Yeast Shell Oral Delivery for Targeted Macrophage Immunomodulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RA treatment options are limited by significant side effects, invasive administration methods, suboptimal targeting precision, and poor patient adherence, with traditional oral drugs struggling to specifically target macrophages and having poor stability in the gastrointestinal environment.
Innovation Solution
The application of yeast shells as oral drugs, derived from Saccharomyces cerevisiae, which are directly used to target macrophages via Dectin-1 receptors, regulating immune function and inhibiting inflammatory responses by acting on mitochondria through oxidative stress and oxidative phosphorylation pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional oral drugs are used for immunomodulation, then patient adherence and convenience are improved, but targeting precision and drug stability in gastrointestinal environment deteriorate
Solution Approach 1:
Yeast shells serve as a natural intermediary carrier that protects immunomodulatory drugs from gastrointestinal degradation while enabling specific targeting of macrophages through Dectin-1 receptor recognition. The yeast shell structure acts as a mediator between oral administration and macrophage delivery, solving both stability and targeting issues simultaneously.
Solution Approach 2:
The invention uses composite yeast shell structures that combine protective properties against gastrointestinal environment with specific immunological recognition capabilities. The yeast shell composite material provides both physical protection and biological targeting functions in a single integrated system.
2Measurement precision
If parenteral administration methods are used, then targeting precision is improved, but patient adherence and convenience deteriorate due to invasive procedures
Solution Approach 1:
The yeast shells enable self-service oral administration that automatically achieves macrophage targeting without requiring invasive procedures. The system serves itself by using the yeast's natural Dectin-1 recognition capability to deliver drugs directly to macrophages through the gastrointestinal tract, eliminating the need for injections while maintaining targeting precision.
Solution Approach 2:
Yeast shells act as an intermediary that bridges oral administration with macrophage-specific delivery, allowing non-invasive routes to achieve targeting precision previously only possible through parenteral methods.
3Object-generated harmful factors
If current RA treatment drugs are used, then inflammatory responses are suppressed, but side effects and safety deteriorate
Solution Approach 1:
The yeast shell delivery system provides local quality by concentrating the immunomodulatory effect specifically at macrophages through Dectin-1 receptor recognition. This localized action at the target cell level suppresses inflammatory responses while minimizing exposure and side effects in non-target tissues and organs.
Solution Approach 2:
Yeast shells serve as a selective intermediary that delivers therapeutic agents specifically to macrophages, thereby suppressing inflammatory responses locally while reducing systemic side effects through targeted delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Yeast shells improve targeting precision, reduce side effects, and enhance therapeutic efficacy by directly acting on macrophages, offering a safer and more effective treatment for RA by inhibiting inflammatory responses and reducing recurrence.
Implementation Method 1
β-glucan, the main component of yeast, is a safe product approved by U.S. Food and Drug Administration (FDA) to be beneficial to the human body. It can be targeted and recognized by Dectin-1 receptors on the surface of macrophages
Implementation Method 2
regulating immune function and inhibiting inflammatory responses by acting on mitochondria through oxidative stress and oxidative phosphorylation pathways
Implementation Method 3
regulating immune function and inhibiting inflammatory responses by acting on mitochondria through oxidative stress and oxidative phosphorylation pathways
Data Source
AI summary
An application of probiotic yeast shells in targeted immunomodulation drugs of inflammatory macrophages is provided, belonging to the field of biomedical technology. As a new type of drug, yeast shells have the characteristics of engineering, convenience, low cost, high patient adherence, safety, and excellent targeting. They are used as oral drugs for the treatment of chronic inflammatory diseases such as rheumatoid arthritis. They act on mitochondria via oxidative stress and oxidative phosphoric acid pathways to inhibit the overactivation of macrophages, reduce the release of inflammatory factors, and alleviate inflammatory responses. They can also promote the phagocytosis and antigen presentation of macrophages, enhance the body's immune defense ability, thereby regulating the immune function of macrophages. Yeast shells show great potential in the preparation of targeted immunomodulation drugs of inflammatory macrophages, providing a theoretical basis for the development of non-invasive, convenient, and safe treatment of chronic inflammatory diseases such as rheumatoid arthritis.